5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to ProfitThe Motley Fool • 06/12/19
Bristol-Myers Squibb And AbbVie: Pharma Dividend Opportunities With Large Margins Of SafetySeeking Alpha • 06/05/19
AbbVie's Skyrizi And Upadacitinib May Not Be Enough To Offset Humira DeclinesSeeking Alpha • 06/03/19
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win BigThe Motley Fool • 05/19/19
AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trialMarket Watch • 05/17/19
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.Market Watch • 05/14/19